Last reviewed · How we verify

FIX — Competitive Intelligence Brief

FIX (FIX) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant coagulation factor replacement. Area: Hematology.

marketed Recombinant coagulation factor replacement Factor IX (coagulation cascade) Hematology Small molecule Live · refreshed every 30 min

Target snapshot

FIX (FIX) — Bioverativ Therapeutics Inc.. FIX is a recombinant coagulation Factor IX that replaces deficient or dysfunctional Factor IX to restore the intrinsic coagulation pathway in patients with hemophilia B.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
FIX TARGET FIX Bioverativ Therapeutics Inc. marketed Recombinant coagulation factor replacement Factor IX (coagulation cascade)
rFIX rFIX Wyeth is now a wholly owned subsidiary of Pfizer phase 3 Recombinant coagulation factor replacement Coagulation Factor IX (FIX)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant coagulation factor replacement class)

  1. Bioverativ Therapeutics Inc. · 1 drug in this class
  2. Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FIX — Competitive Intelligence Brief. https://druglandscape.com/ci/fix. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: